| Title |
Development of autotaxin inhibitors: A series of zinc binding triazoles
|
|---|---|
| Published in |
Bioorganic & Medicinal Chemistry Letters, May 2018
|
| DOI | 10.1016/j.bmcl.2018.05.030 |
| Pubmed ID | |
| Authors |
Christopher G. Thomson, Darren Le Grand, Mark Dowling, Cara E. Brocklehurst, Colin Chinn, Lucy Elphick, Michael Faller, Mark Freeman, Vikki Furminger, Cornelia Gasser, Ahmed Hamadi, Elizabeth Hardaker, Victoria Head, Johan C. Hill, Diana I. Janus, David Pearce, Anne-Sophie Poulaud, Emily Stanley, Lilya Sviridenko |
| Abstract |
A series of inhibitors of Autotaxin (ATX) has been developed using the binding mode of known inhibitor, PF-8380, as a template. Replacement of the benzoxazolone with a triazole zinc-binding motif reduced crystallinity and improved solubility relative to PF-8380. Modification of the linker region removed hERG activity and led to compound 12 - a selective, high affinity, orally-bioavailable inhibitor of ATX. Compound 12 concentration-dependently inhibits autotaxin and formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic experiments. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 35% |
| Student > Master | 4 | 24% |
| Researcher | 2 | 12% |
| Student > Bachelor | 1 | 6% |
| Unknown | 4 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 7 | 41% |
| Biochemistry, Genetics and Molecular Biology | 3 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Mathematics | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 3 | 18% |